Objective. The aim of this study was to evaluate the clinical characteristics of patients with anti-melanoma differentiationassociated gene 5 (MDA5) antibodypositive inflammatory myositis, and the change in anti-MDA5 antibody titres before and after onset.
Introduction
PM and DM are systemic rheumatic disorders that involve the muscles, skin and lungs. Several autoantibodies are detected in PM/DM patient sera, some of which are specific to PM/DM (myositis-specific autoantibodies; MSAs) or myositis overlap syndromes (myositis-associated autoantibodies; MAAs). Notably, each MSA/MAA is closely associated with complications, reactivity to therapy, and prognosis in PM/DM patients [1] . Interstitial lung disease (ILD) is one of the most important prognostic factors in PM/DM patients [2] . Anti-aminoacyl-transfer RNA synthetase antibody, anti-PM/Scl-75 antibody and anti-melanoma differentiationassociated gene 5 (MDA5) antibody have been reported as autoantibodies that are associated with ILD [3] . Anti-MDA5 antibodies were initially reported in 2005 in cases of clinically amyopathic DM (CADM) with rapidly progressive ILD [4] , and in recent years they have also been identified in general DM patients, including those with CADM [57] . Although the prognosis of DM with rapidly progressive ILD (RP-ILD) has improved as a result of combination therapy with CSs, calcineurin inhibitor and IV pulse CYC (IVCY) [8] , the disease is still refractory and fatal in 2030% of cases. In this study, we analysed anti-MDA5 antibodypositive patients in terms of both clinical characteristics and changes in anti-MDA5 antibody titres over time.
Methods

Patients
In this study, we retrospectively examined patients who were admitted to Juntendo University Hospital from 2008 to 2016. A total of 109 patients were diagnosed with PM, DM or CADM according to the diagnostic criteria of Bohan and Peter [9] or Sontheimer [10] as appropriate. Specific rashes, including heliotrope rash, Gottron's sign and Gottron's papules were used to define DM and CADM. We enrolled 105 patients in this study, because in the remaining four patients we were not able to obtain autoantibody profiles at the time of the diagnosis. All 105 patients had active disease, and were treated with high-dose prednisolone with or without an immunosuppressant. This study was approved by the ethical committee of Juntendo University Hospital. All patients provided written informed consent in accordance with the Declaration of Helsinki.
Clinical evaluation and outcomes
Clinical data, including patient demographics, clinical manifestations, laboratory data, treatments, outcomes, and causes of death, were obtained from medical records. Treatment included all therapies being received by patients at the initial admission. The primary outcome was disease-non-specific mortality. The existence of myositis was determined by manual muscle testing, EMG, and serum levels of creatine kinase (CK) and aldolase (ALD). Dermatitis was evaluated by physical examination. Pulmonary disease was assessed by chest radiography and high-resolution CT. A malignancy survey was performed in all patients. RP-ILD was defined as ILD showing progression within 1 month of the onset of respiratory symptoms [4] . Anti-MDA5 antibody titres were measured by ELISA using the MESACUP anti-MDA5 test (Medical & Biological Laboratories, Nagoya, Japan). Other MSAs and MAAs (including anti-Jo-1, anti-EJ, Anti-PL7, anti-PL12, Anti-OJ, anti-SRP, anti-Mi-2, anti-PM/Scl75, anti-PM/Scl100 and anti-Ku) were detected by a commercially available line immunoassay (Euroline Myositis Profile 3, EUROIMMUN, Luebeck, Germany) according to the manufacturer's instructions.
Statistical analysis
The survival rates for each group were compared by plotting KaplanMeier curves and evaluating them with the log-rank test. To compare demographics and disease characteristics, the Student's t test was used for normally distributed variables, and the?MannWhitney U test was employed for non-normally distributed variables. To compare changes in anti-MDA5 antibody titres over time, we used the two-way repeated measures analysis of variance (ANOVA). Prior to the ANOVA test, we examined equality of variances with Levene's test. Statistical analyses were carried out using the SPSS 23.0 software program (SPSS, Chicago, IL, USA). Values of P < 0.05 were considered significant.
Results
Clinical features of anti-MDA5positive patients
The mean follow-up period was 40 months (range 1108 months). Anti-MDA5 antibody was detected in 24 patients (22.9%), with a mean (S.D.) value of 165 U/ml (35). Table 1 shows the characteristics at diagnosis, treatment details at first admission and survival rates in all cases and in the anti-MDA5 antibodypositive and negative groups. All patients with anti-MDA5 antibody had both dermatitis and ILD. The ferritin level and the frequencies of DM, CADM, ILD and RP-ILD were significantly higher in the anti-MDA5 antibodypositive group. In contrast, this group exhibited significantly lower CK and ALD levels, as well as frequencies of ANA titres 5 1:160 and cytoplasmic ANA staining patterns. The overall study group had the following concurrent autoimmune diseases: 9 cases of SSc, 6 of SLE, 5 of RA, 11 of SS, 2 of pulmonary arterial hypertension, 6 of Hashimoto disease, 1 of Graves' disease and 1 of slowly progressive insulin-dependent diabetes mellitus. Among these patients, anti-MDA5 antibody was detected in two patients, one of whom was complicated with RA and another with SS. No anti-MDA5 antibodypositive patients had malignancies, whereas one case each of ovarian cancer, lung cancer and renal cell carcinoma occurred in the anti-MDA5 antibodynegative patients.
Anti-aminoacyl-transfer RNA synthetase antibodies (excluding anti-KS antibodies) were detected in 30% of patients, as follows: anti-Jo-1 in 11 patients, anti-PL7 in 8, anti-PL12 in 5, anti-OJ in 1 and anti-EJ in 7. In addition, anti-Mi-2, anti-Ku and anti-PM/Scl75 were detected in six, three and four patients, respectively.
All patients received daily oral prednisolone with or without 500 or 1000 mg of daily i.v. methylprednisolone pulse therapy for 3 consecutive days. Fifty-four patients were treated with an immunosuppressant, that is, CYC, MTX or calcineurin inhibitors (ciclosporin and tacrolimus). The initial dose of oral prednisolone and the number of steroid pulses were higher in the anti-MDA5 antibodypositive group, whereas the frequency of MTX was lower. Twelve anti-MDA5 antibodypositive RP-ILD patients received an intensive regimen of combined www.rheumatology.oxfordjournals.org immunosuppressive therapy (high-dose CSs, calcineurin inhibitors and IVCY).
The mean survival time of all patients was 95 months, and the results of the log-rank test for the anti-MDA5 antibodypositive and negative groups was P < 0.01 (Fig. 1A) . Twelve patients died during the observation period, with the following causes of death: respiratory failure with ILD in eight patients, colorectal perforation in two, sepsis in one and pneumocystis pneumonia in one. Relapse was not observed in the anti-MDA5 antibodypositive group.
Titres of anti-MDA5 antibodies in preclinical and active disease Figure 1B shows serial titres of anti-MDA5 antibody over time, using frozen serum samples from two patients before the onset of PM/DM with RP-ILD. One patient who was followed due to suspected SS was found to have positive titres of anti-MDA5 antibody even 2 years before disease onset. Figure 1C shows changes in titres from 24 anti-MDA5 antibodypositive patients after the onset of active disease; anti-MDA5 antibody titres decreased after commencement of treatment in most cases. In Fig. 1D , the first 6 months were highlighted because all non-survivors died within 4 months. The rates at which anti-MDA5 antibody titres decreased did not differ between survivors and non-survivors within this duration. Figure 1E shows a comparison of anti-MDA5 antibody titres at baseline and after treatment for 17 cases, including four fatal cases. Two-way repeated measures ANOVA identified a significant difference between the survivor and non-survivor groups in terms of the rate of decrease in anti-MDA5 antibody titres (P < 0.01). In contrast, there was no significant difference in the titre decline rate between the four survivors and the three non-survivors from disease onset to 2 months afterward ( Fig. 1F , P = 0.12).
Discussion
In this study, we noted the clinical characteristics of patients with anti-MDA5 antibodypositive inflammatory myositis, and determined the changes in anti-MDA5 antibody titres before and after disease onset. The anti-MDA5 antibody positivity rate of 22.9% was consistent with the range of 1048% in previous studies of patients with PM/DM [11] . The anti-MDA5 antibody was first reported in 2005 as the anti-CADM-140 antibody (anti-clinically amyopathic DM-140 antibody), thought to bind to a 140-kDa protein in the cytoplasm [4], but it became clear afterwards that it bound to MDA5, and it was thus renamed the anti-MDA5 antibody [12] . MDA5 is a cytoplasmic retinoic acidinducible gene-Ilike receptor involved in viral dsRNA recognition, and its stimulation leads to the expression of type 1 interferon and inflammatory cytokines [13] . Previous reports have shown an association between anti-MDA5 antibody and RP-ILD, particularly RP-ILD with CADM [47]; however, the pathological mechanism is unclear [14] .
All 24 anti-MDA5 antibodypositive patients in this study were complicated with dermatitis and ILD; 71% had RP-ILD, while conversely, 77% of RP-ILD patients were anti-MDA5 antibodypositive. A meta-analysis showed that the pooled sensitivity and specificity of anti-MDA5 antibody for RP-ILD were 77% (95% CI: 64, 87%) and 86% (95% CI: 79, 90%), respectively [15] .
The initial dose of oral prednisolone, the frequency of steroid pulse therapy and the proportion of patients receiving combination therapy were all higher in the anti-MDA5 antibodypositive group due to severe disease or the prediction of severe disease. On the other hand, MTX was used less frequently in the anti-MDA5 antibodypositive group because all cases in this group were complicated with ILD. Levels of CK and ALD were lower in anti-MDA5 antibodypositive patients, indicating the frequency of CADM in this group. The ferritin level was higher in anti-MDA5 antibodypositive patients, which is consistent with previous reports [16, 17] .
Although MDA5, one of the retinoic acidinducible gene-Ilike receptors, is located in the cytoplasm, the frequency of the cytoplasmic pattern of ANA staining was significantly lower in the anti-MDA5 antibodypositive group in this study. Differences in the sensitivity or measurement methods of the assays in this study might have influenced the results, and further research is necessary to investigate this issue.
The intensive regimen of combined immunosuppressive therapy (high-dose CSs, calcineurin inhibitor and IVCY) was previously found to improve the survival rate of anti-MDA5 antibodypositive patients from 28.6 to 75.0% [8] .
Of the anti-MDA5 antibodypositive patients with RP-ILD in this study, 71% received this intensive regimen, and the survival rate of 71% was consistent with that of the above report. In two cases we observed a change in anti-MDA5 antibody titres before disease onset. One case became anti-MDA5 antibody positive 2 years before disease onset, while in the other case, positivity was observed for the first time at disease onset. These results suggest that there may be a positive anti-MDA5 antibody titre before the onset, and that anti-MDA5 antibodies may increase to a high titre just before the onset.
Sato et al. [18] reported that the mean titre of anti-MDA5 antibody significantly decreased after treatment in surviving patients, whereas in non-surviving patients the mean titre did not decrease and instead remained at a high level. Several reports have demonstrated a disappearance of or decrease in anti-MDA5 antibodies in cases of CADM with ILD after treatment [17, 19, 20] . In this study, anti-MDA5 antibody titres decreased within 2 months in both survivors and fatal cases. The titres were observed to decrease significantly later, during remission in survivors. Taken together, we consider that changes in anti-MDA5 antibody titres are useful for evaluating disease activity in RP-ILD; however, the initial decrease after commencement of treatment may not always represent subsequent patient survival. A recent study monitored anti-MDA5 antibody levels to predict relapse of RP-ILD in patients with CADM or DM [20] and, as in our study, found that some patients had sustained positive anti-MDA5 antibody titres after the induction of remission. Our findings do not indicate there is no value in monitoring anti-MDA5 antibody after remission, and some patients included in our study should continue to have anti-MDA5 antibody measurements performed.
The limitations of this study are the small number of patients; the retrospective, single-centre design; and considerable missing data for anti-MDA5 antibody titres after 1 and 2 months of treatment, including those for patients who died within 1 month (Fig. 1F) . As a result, anti-MDA5 antibody titres before treatment between survivor and non-survivor groups differ from previous reports [7, 18] .
In conclusion, reduction in anti-MDA5 antibody titres was associated with positive patient prognosis; however, it may also be observed in fatal cases. Long-term longitudinal study of anti-MDA5 antibodypositive patients should be conducted.
